Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

LXRX
Lexicon Pharmaceuticals, Inc.
stock NASDAQ

Market Open
Jul 10, 2025 11:49:22 AM EDT
1.18USD+10.748%(+0.11)2,713,149
1.18Bid   1.20Ask   0.02Spread
Pre-market
Jul 10, 2025 9:24:30 AM EDT
1.07USD-0.009%(0.00)15,320
After-hours
Jul 9, 2025 4:56:30 PM EDT
1.08USD+1.399%(+0.01)0
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 13, 2022
09:00AM EST  NDA submitted for sotagliflozin in heart failure with an expected launch in 2H 2022, if approved   GlobeNewswire Inc
Jan 4, 2022
04:05PM EST  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicons chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. ET.   GlobeNewswire Inc
Dec 31, 2021
06:05AM EST  A Peek Into The Markets: US Stock Futures Edge Lower On Final Trading Day Of 2021   Benzinga
Dec 30, 2021
04:08PM EST  Lexicon Submits New Drug Application For Sotagliflozin For Treatment Of Heart Failure In Adults With Type 2 Diabetes   Benzinga
04:05PM EST  Lexicon Submits New Drug Application for Sotagliflozin for the   GlobeNewswire Inc
Nov 15, 2021
03:03PM EST  Lexicon's Sotagliflozin Shows Benefits in Heart Failure, Blood Glucose Control   Benzinga
Nov 14, 2021
08:35AM EST  Post hoc analysis of pooled clinical data from the SOLOIST and SCORED trials supporting benefit of sotagliflozin presented at the virtual American Heart Association Scientific Sessions 2021, including:   GlobeNewswire Inc
Nov 9, 2021
11:46AM EST  New Analysis To Be Presented At The American Heart Association Scientific Sessions 2021 Evaluating Cardiovascular Benefits Across Baseline Kidney Function   Benzinga
08:00AM EST  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that a new analysis of sotagliflozin results from the SOLOIST and SCORED Phase 3 outcomes studies will be presented at the virtual American Heart Association Scientific Sessions 2021.   GlobeNewswire Inc
Nov 3, 2021
05:23PM EDT  Lexicon Pharmaceuticals Q3 EPS $(0.16) Beats $(0.18) Estimate, Sales $23.00K Down From $6.63M YoY   Benzinga
05:18PM EDT  Recap: Lexicon Pharmaceuticals Q3 Earnings   Benzinga
09:10AM EDT  Earnings Scheduled For November 3, 2021   Benzinga
Sep 15, 2021
08:00AM EDT  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicons president and chief executive officer, will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, September 21, 2021 at 10:45 a.m. ET.   GlobeNewswire Inc
Aug 30, 2021
07:00AM EDT  New guidelines from the European Society of Cardiology recommend addition of SGLT inhibitors to standard of care for patients with acute and chronic heart failure.   GlobeNewswire Inc
Aug 23, 2021
06:10AM EDT  Lexicon's Sotagliflozin Demonstrates Additional Compelling Benefits in Reducing Cardiovascular Endpoints: Results from Soloist and Scored Trials   Benzinga
06:09AM EDT  Rapid benefit of sotagliflozin supported by data from the SOLOIST and SCORED trials presented at ESC Congress 2021 - The Digital Experience, including:   GlobeNewswire Inc
Aug 16, 2021
10:31AM EDT  Overview Of Value Stocks In The Healthcare Sector   Benzinga
Aug 6, 2021
04:14PM EDT  Lexicon S-3 Shows Registration For $200M Mixed Securities Shelf Offering   Benzinga
Jul 30, 2021
07:54AM EDT  The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs   Benzinga
07:21AM EDT  Lexicon Pharmaceuticals: Q2 Earnings Insights   Benzinga
07:10AM EDT  Lexicon Pharmaceuticals Q2 EPS $(0.13) Beats $(0.16) Estimate, Sales $200.00K Beat $10.00K Estimate   Benzinga
07:01AM EDT  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that Craig Granowitz, M.D., Ph.D. will join the company as senior vice president and chief medical officer, effective August 2, 2021.   GlobeNewswire Inc
07:00AM EDT  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2021 and provided an update on key milestones.   GlobeNewswire Inc
04:13AM EDT  Earnings Scheduled For July 30, 2021   Benzinga
Jul 21, 2021
07:06AM EDT  Lexaria Highlights VIRAL-A20-3 STudy Results Showing 'Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects'   Benzinga
Jun 25, 2021
08:00AM EDT  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today there will be a symposium highlighting sotagliflozin followed by a live video question and answer period during the American Diabetes Associations 81st Scientific Sessions being held virtually June 25, 2021 through June 29, 2021:   GlobeNewswire Inc
May 26, 2021
04:15PM EDT  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicons president and chief executive officer, will present at the 2021 Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 11:30 a.m. ET.   GlobeNewswire Inc
May 13, 2021
04:15PM EDT  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today there will be two virtual presentations highlighting sotagliflozin during the American College of Cardiologys 70th Annual Scientific Session (ACC.21) being held May 15, 2021 through May 17, 2021:   GlobeNewswire Inc
May 6, 2021
05:36PM EDT  Recap: Lexicon Pharmaceuticals Q1 Earnings   Benzinga
05:14PM EDT  Lexicon Pharmaceuticals Q1 EPS $(0.15) Beats $(0.16) Estimate, Sales $27.00K Miss $1.68M Estimate   Benzinga
04:17AM EDT  Earnings Scheduled For May 6, 2021   Benzinga
Apr 8, 2021
04:35PM EDT  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, Lexicons executive vice president, corporate and administrative affairs and chief financial officer, will participate in a live fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 10:15 a.m. ET.   GlobeNewswire Inc
Mar 10, 2021
04:10PM EST  Lexicon Pharmaceuticals Q4 EPS $(0.04) Beats $(0.28) Estimate, Sales $200.00K Beat $110.00K Estimate   Benzinga
04:10PM EST  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and full-year ended December 31, 2020 and provided an update on key milestones.   GlobeNewswire Inc
07:26AM EST  The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link   Benzinga
04:04AM EST  Earnings Scheduled For March 10, 2021   Benzinga
Mar 9, 2021
10:24AM EST  Earnings Preview: Lexicon Pharmaceuticals   Benzinga
Mar 6, 2021
10:58AM EST  The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings   Benzinga
Mar 4, 2021
04:05PM EST  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter and full-year 2020 financial results on Wednesday, March 10, 2021 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.   GlobeNewswire Inc
Feb 3, 2021
07:31AM EST  The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision   Benzinga
Jan 29, 2021
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 29, 2021   Benzinga
08:55AM EST  Wedbush Downgrades Lexicon Pharmaceuticals to Neutral, Raises Price Target to $8   Benzinga
07:40AM EST  JP Morgan Upgrades Lexicon Pharmaceuticals to Neutral, Announces $7 Price Target   Benzinga
Jan 15, 2021
07:57AM EST  The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges   Benzinga
Jan 14, 2021
02:33PM EST  Mid-Afternoon Market Update: Dow Rises 75 Points; Acacia Communications Shares Spike Higher   Benzinga
12:27PM EST  Mid-Day Market Update: Volt Information Sciences Drops After Q4 Results; Lexicon Pharmaceuticals Shares Jump   Benzinga
10:27AM EST  Mid-Morning Market Update: Markets Open Higher; Delta Air Lines Posts Wider-Than-Expected Loss   Benzinga
10:26AM EST  Shares of Lexicon Pharmaceuticals, Inc. (LXRX) are currently gaining over 35% after the company said it received a regulatory feedback that clears a key hurdle for partnership discussions around sotagliflozin in heart failure.   RTTNews
08:16AM EST  Lexicon Gets FDA Feedback That Results Of SOLOIST, SCORED Phase 3 Studies Can Support NDA Submission   RTTNews
08:00AM EST  Lexicon Pharmaceuticals Provides Regulatory Update on   GlobeNewswire Inc
Jan 6, 2021
08:00AM EST  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicons president and chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 2:50 p.m. ET.   GlobeNewswire Inc
Dec 31, 2020
08:08AM EST  Lexicon Begins Patient Dosing In RELIEF-PHN 1 Study Of LX9211 For Post-herpetic Neuralgia   RTTNews
08:01AM EST  Lexicon Pharma Reports Commencement Of Dosing In Phase 2 Study Of LX9211 In Post-Herpetic Neuralgia   Benzinga
08:00AM EST  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing in RELIEF-PHN 1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of post-herpetic neuralgia. LX9211 is a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1).   GlobeNewswire Inc
Dec 20, 2020
07:19AM EST  Notable Insider Buys of the Past Week: Mylan, Sonabank, Steak 'n Shake, U-Haul And More   Benzinga
Dec 16, 2020
04:52PM EST  Wunong Net Technology Co. Ltd. (WNW) - Shares of the Chinese e-commerce company gained nearly 20% in after hours trading on top of 400% surge in regular trading on Wednesday, its second day of trading since its IPO. On Tuesday, its first day of trading, Wunong shares rose 141%. The Shenzhen-based company had raised $30 million in its IPO.   RTTNews
04:06PM EST  Lexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience; Lexicon Will Receive An Upfront Payment And Is Eligible To Receive Milestone Payments Totaling Up To $5.3M In The Aggregate   Benzinga
04:05PM EST  Lexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience   GlobeNewswire Inc
Dec 11, 2020
03:08PM EST  Lexicon Pharmaceuticals shares were trading higher after the company announced it has received Fast Track designation from the FDA for the development of LX9211 in diabetic peripheral neuropathic pain.   Benzinga
08:16AM EST  Lexicon Pharmaceuticals, Inc. (LXRX) has received Fast Track designation from the FDA for the development of LX9211 in diabetic peripheral neuropathic pain. LX9211 is a potent, orally delivered, selective small molecule inhibitor of adapter-associated kinase 1 (AAK1).   RTTNews
08:10AM EST  Lexicon Receives Fast Track Designation From FDA For Development Of LX9211   RTTNews
08:09AM EST  Lexicon Plans Direct Offering Of 20.31 Mln Shares At $3.20 Per Share   RTTNews
08:02AM EST  Lexicon Pharma Prices 20.3M Shares At $3.20/Share   Benzinga
08:02AM EST  Lexicon Announces Offering of Common Stock   GlobeNewswire Inc
07:38AM EST  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of LX9211 in diabetic peripheral neuropathic pain.   GlobeNewswire Inc
07:38AM EST  Lexicon Pharma Reports Fast Track Designation For LX9211 For Diabetic Peripheral Neuropathic Pain   Benzinga
Dec 8, 2020
02:31PM EST  Mid-Afternoon Market Update: Dow Jumps 150 Points; Stitch Fix Shares Gain On Upbeat Q1 Earnings   Benzinga
12:28PM EST  Mid-Day Market Update: US Stocks Turn Positive; Arcturus Therapeutics Shares Plunge   Benzinga
09:36AM EST  Benzinga's Top Upgrades, Downgrades For December 8, 2020   Benzinga
07:51AM EST  Citigroup Upgrades Lexicon Pharmaceuticals to Buy, Raises Price Target to $6   Benzinga
Nov 23, 2020
12:19PM EST  The November Market Grinds Along   Benzinga
Nov 19, 2020
05:53AM EST  What's moving these stocks in the pre-market hours today?   RTTNews
Nov 18, 2020
09:39AM EST  Lexicon Pharmaceuticals shares were trading higher after Gabelli & Co upgraded the stock from Hold to Buy.   Benzinga
06:14AM EST  Gabelli & Co. Upgrades Lexicon Pharmaceuticals to Buy   Benzinga
Nov 17, 2020
02:46PM EST  Mid-Afternoon Market Update: Nasdaq Turns Positive; Cinedigm Shares Slide   Benzinga
12:37PM EST  Mid-Day Market Update: Sequential Brands Gains After Q3 Results; Brainstorm Cell Therapeutics Shares Plunge   Benzinga
11:00AM EST  Why Lexicon Pharmaceuticals Stock Is Trading Higher Today   Benzinga
10:26AM EST  Yahoo Finance Trending Stocks For Tuesday, Nov. 17, 2020: TSLA, FCEL, COST, HD, PLUG, WMT, CVS, ABBV, WBA, GDRX, SE, VTRS, AMZN, LXRX, CTIB, BCLI, WWR, DQ, MOGO, SQBG, BLNK, RAD, MCK, RIDE, BMY, TMUS, RMED, MAPT, IQ   Benzinga
Nov 16, 2020
10:02PM EST  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits in patients treated with sotagliflozin as compared with placebo.   GlobeNewswire Inc
08:00AM EST  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following conference:   GlobeNewswire Inc
Nov 10, 2020
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
Nov 3, 2020
07:38AM EST  The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure   Benzinga
Nov 2, 2020
09:10AM EST  Stocks Trading Near 52-Week Lows Before Open On Monday, Nov. 2, 2020: CLSN, MRTN, UTSI, LXRX, TTNP, ORTX, ARTL, PEI, CBL   Benzinga
Oct 30, 2020
08:09AM EDT  The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts   Benzinga
Oct 29, 2020
08:52AM EDT  Stocks Trading Near 52-Week Lows Before Open On Thursday, Oct. 29, 2020: WORX, OXY, HYLN, LXRX, TS, BTU, TCDA, GILD, ETTX, PBF, TEF, EURN   Benzinga
08:02AM EDT  Lexicon Pharmaceuticals: Q3 Earnings Insights   Benzinga
07:30AM EDT  The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal   Benzinga
06:50AM EDT  Lexicon Pharmaceuticals Q3 EPS $(0.43) Misses $0.26 Estimate, Sales $6.63M Miss $16.87M Estimate   Benzinga
06:00AM EDT  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2020 and provided an update of key milestones.   GlobeNewswire Inc
04:08AM EDT  Earnings Scheduled For October 29, 2020   Benzinga
Oct 27, 2020
08:25AM EDT  The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings   Benzinga
08:00AM EDT  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2020 financial results on Thursday, October 29, 2020 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT) that day to discuss the financial results and to provide a clinical update.   GlobeNewswire Inc
Oct 22, 2020
07:52AM EDT  The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat   Benzinga
Sep 24, 2020
05:38AM EDT  Lexicon Pharmaceuticals Announced Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness   Benzinga
Sep 23, 2020
06:43PM EDT  Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible   GlobeNewswire Inc
Sep 14, 2020
09:46AM EDT  A Look Into Healthcare Sector Value Stocks   Benzinga
Sep 8, 2020
04:05PM EDT  Lexicon Pharmaceuticals Completes the Sale of XERMELO to TerSera   GlobeNewswire Inc
Sep 4, 2020
10:37AM EDT  Lexicon Pharmaceuticals shares are trading higher after the company announced the commencement of a patient dosing in the RELIEF-DPN-1 Phase 2 clinical study of its LX9211 in patients with diabetic peripheral neuropathic pain.   Benzinga
08:04AM EDT  Lexicon Pharma Begins Patient Dosing In RELIEF-DPN-1 Phase 2 Clinical Study Of LX9211   RTTNews
08:03AM EDT  Lexicon Pharmaceuticals Announces Commencement Of Patient Dosing In RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 In Patients With Diabetic Peripheral Neuropathic Pain   Benzinga
08:00AM EDT  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing with blinded study drug in RELIEF-DPN-1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of diabetic peripheral neuropathic pain. LX9211 is a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1).   GlobeNewswire Inc
Sep 3, 2020
06:00PM EDT  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following conferences:   GlobeNewswire Inc
Aug 24, 2020
11:36AM EDT  A Look Into Healthcare Sector Value Stocks   Benzinga
Aug 10, 2020
11:52AM EDT  5 Value Stocks To Watch In The Healthcare Sector   Benzinga
Aug 4, 2020
06:18AM EDT  Lexicon Pharmaceuticals Intends To Implement Reduction In Force, Which Will Reduce Workforce By About 50% Related To Tersera Therapeutics Agreement   Benzinga
Aug 3, 2020
09:35AM EDT  Lexicon Pharmaceuticals shares are trading higher. The Company last week announced it will sell Xermelo to GTCR and TerSera Therapeutics for an upfront purchase price of approximately $159 million along with potential milestone payments. NOTE: GTCR issued a press release today detailing the acquisition.   Benzinga
07:33AM EDT  GTCR And TerSera Therapeutics Issue Press Release Detailing Definitive Agreement To Acquire Xermelo From Lexicon Pharmaceuticals For $159M Plus Potential Milestones. BZ NOTE: Lexicon Announced Sale Of Xermelo Last Week   Benzinga
07:29AM EDT  GTCR And TerSera Therapeutics Enter Definitive Agreement To Acquire Xermelo From Lexicon Pharmaceuticals For $159M Plus Potential Milestones   Benzinga
07:27AM EDT  TerSera Therapeutics Enters Definitive Agreement To Acquire Product Xermelo From Lexicon   RTTNews
07:25AM EDT  GTCR and TerSera Therapeutics Announce Acquisition of Xermelo   PR Newswire
Jul 30, 2020
08:44AM EDT  Lexicon Says Is Realigning Business Around Research And Development Assets, With Focus On Phase 2 LX9211 Neuropathic Pain Program   Benzinga
07:21AM EDT  Lexicon Pharma Shares To Resume Trade At 7:45 a.m. EDT   Benzinga
07:21AM EDT  UPDATE: Lexicon May Receive Added Development, Regulatory, Sales Milestone Payments Of Up To $65M   Benzinga
07:20AM EDT  Lexicon Pharma Reports Deal With TerSera Therapeutics For Sale Of XERMELO For $159M In Cash   Benzinga
07:18AM EDT  Lexicon Pharmaceuticals Q2 EPS $(0.65) Misses $(0.61) Estimate, Sales $9.16M Beat $8.83M Estimate   Benzinga
07:15AM EDT  Phase 2 Study for Diabetic Peripheral Neuropathic Pain Underway, Additional Studies Planned in Other Areas of Neuropathic Pain   GlobeNewswire Inc
07:10AM EDT  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) and TerSera Therapeutics LLC announced today that they have entered into an asset purchase and sale agreement for the sale to TerSera of Lexicons rights, title and interest in XERMELO (telotristat ethyl).   GlobeNewswire Inc
07:01AM EDT  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended June 30, 2020.   GlobeNewswire Inc
06:59AM EDT  Lexicon Pharma Shares Halted News Pending   Benzinga
04:06AM EDT  Earnings Scheduled For July 30, 2020   Benzinga
Jul 27, 2020
01:54AM EDT  5 Value Stocks In The Healthcare Sector   Benzinga
Jul 23, 2020
07:00AM EDT  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2020 financial results on Thursday, July 30, 2020 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT) that day to discuss the financial results and to provide a business update.   GlobeNewswire Inc
Jul 21, 2020
07:09AM EDT  Lexicon: All Four Phase 3 Sotagliflozin Studies Met Primary Objectives Of Lowering A1C In Patients With Type 2 Diabetes   RTTNews
07:05AM EDT  Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies In Type 2 Diabetes   Benzinga
07:00AM EDT  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline data from four Phase 3 sotagliflozin studies in type 2 diabetes: SOTA-MONO, SOTA-SU, SOTA-GLIM and SOTA-INS. The final results of these studies will be preserved for upcoming medical congresses and publications.   GlobeNewswire Inc
Jul 20, 2020
07:00AM EDT  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that four posters highlighting XERMELO (telotristat ethyl) will be presented at the virtual Cholangiocarcinoma Foundation Annual Conference (July 22-24).   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC